Integrated molecular analysis of clear-cell renal cell carcinoma

By Yusuke Sato, T. Yoshizato, Y. Shiraishi, S. Maekawa, Y. Okuno, T. Kamura, Teppei Shimamura, A. Sato-Otsubo, G. Nagae, Hiromichi Suzuki and 19 more. Nature Genetics, 2013

1,154 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/bc50375e60e3fb40dd26b82450ff89f34a668b9e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pulmonary and Respiratory Medicine

Donna D. Zhang

Citations in the corpus

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas (2018, positive): “For example, TCEB1, which forms a complex with VHL, was identified as a prominent driver gene in KIRC (kidney renal clear cell carcinoma) (Sato et al., 2013).”
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma (2017, background): “Notably, BAP1 mutations have been associated with DNA hypermethylation in CCA and renal cell carcinoma (13,40).”
p62 links autophagy and Nrf2 signaling. (2015, background): “Somatic mutations in Nrf2 or its negative regulators (Keap1 and Cul3) have been shown to be responsible for the high levels of Nrf2 in certain tumors, such as lung cancer, melanoma, renal clear cell carcinoma, and hepatocellular carcinoma [53–57].”
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016, methodology): “In order to validate that the three immune infiltration clusters are not unique to the TCGA ccRCC cohort, we utilized a separate publicly available dataset of 101 ccRCC tumors for which comparable multi-platform data were available [29] and refer to it as the SATO dataset from here on.”
TANRIC: An interactive open platform to explore the function of lncRNAs in cancer (2015, neutral): “In addition, we obtained the RNA-seq files of 531 samples from another three independent studies, including LUAD (13), clear-cell renal cell carcinoma (14), and glioblastomas (15).”
The emerging role of the Nrf2–Keap1 signaling pathway in cancer (2013, background): “Gain-of-function mutations in NRF2 and loss-of-function mutations in KEAP1 and CUL3 have been identified in several human cancers (Padmanabhan et al. 2006; Singh et al. 2006; Nioi and Nguyen 2007; Ohta et al. 2008; Shibata et al. 2008a; Li et al. 2011; Ooi et al. 2013; Sato et al. 2013).”
Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance (2017, neutral): “6b, c), which resembles the Elongin C-encoding TCEB1 hotspot mutants in clear cell renal carcinoma, resulting in deficiencies in the ability of Cullin 2/Elongin B/C/VHL E3 ligase complex to promote HIF1 α degradation 26.”
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal (2018, neutral): “Driver genes were selected from genes that were frequently mutated in TCGA (accessed in April 2015) or highlighted in relevant studies (Arai et al., 2014; Sato et al., 2013; Scelo et al., 2014).”